Table 4.
Comparison between pre-clinical/clinical inhibitors and pomegranate/pomegranate compounds having NF-κB and MAPK signaling pathways inhibitory potential
| Inhibitor name |
Cancer |
Results |
References |
|---|---|---|---|
| Pre-clinical/clinical NF-κB and MAPK inhibitors | |||
| Bortezomib | Lung cancer | Suppress inflammation, reduce metastasis, retarded cell proliferation, and induced apoptotic conditions | [265,266] |
| Bevacizumab | Lung cancer | [267] | |
| Dabrafenib | Lung cancer | [268] | |
| SB202190 | Gastric cancer | [260] | |
| Talmapimod | Multiple myeloma | [260] | |
| Pimasertib | Metastatic pancreatic cancer | [269] | |
| Pomegranate NF-κB and MAPK inhibitors | |||
| Tannin rich pomegranate fruit extract | Skin cancer | Inhibits cancer cell proliferation, induce apoptosis, decrease inflammation and metastasis | [175] |
| Pomegranate fruit extract | Skin cancer | [93] | |
| Pomegranate fruit extract | Skin cancer | [177] | |
| Pomegranate fruit extract | Lung cancer | [106] | |
| Pomegranate fruit extract | Breast cancer | [270] | |
| Punicalagin | Colon cancer | [47] | |
| Ellagic acid | Colorectal cancer | [151] | |
MAPK: Mitogen-activated protein kinase; NF-κB: Nuclear factor kappa B.